期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨硬化蛋白在骨组织改建中作用的分子机制 被引量：3

Molecular mechanism of sclerostin on bone remoldling
下载PDF
导出
摘要 骨硬化蛋白是一种对成骨细胞具有抑制作用的蛋白,由骨细胞特异分泌后转运至成骨细胞,通过影响Wnt信号通路对成骨作用产生抑制。外部条件如激素水平、机械刺激以及低氧环境等都能影响骨硬化蛋白的表达。骨硬化蛋白抗体能够促进成骨细胞活性从而提高骨量,但其临床疗效和安全性还需进一步的研究确定。 Sclerostin is a negative regulator of osteoblasts. It is expressed exclusively by osteocytes which is transported to osteoblasts at the bone surface to inhibit bone formation. The mechanism of the sclerostin on bone is related to Wnt signaling pathway. The expression of sclerostin is also affected by the hormone, mechanical strain and hypoxia. The antibody to sclerostin has the ability to stimulate osteoblast activity and increase the bone mass, but the curative effect and safety need to estimate.
作者 林婷婷 陆尔奕
机构地区 上海交通大学医学院附属第九人民医院口腔修复科
出处 《国际口腔医学杂志》 CAS 2012年第2期269-272,共4页 International Journal of Stomatology
关键词 骨硬化蛋白 骨改建 WNT信号通路 sclerostin bone remoldling Wnt signaling pathway
分类号 R681 [医药卫生—骨科学]
  • 相关文献

参考文献29

  • 1van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist[J]. J Exp Med, 2004, 199 (6): 805-814.
  • 2Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone fonnation[J]. FASEB J, 2005, 19 (13): 1842-1844.
  • 3Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) [J]. Hum Mol Genet, 2001, 10 (5) : 537-543.
  • 4Brunkow ME, Gardner JC, Van Ness J, et al Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein[J]. Am J Hum Genet, 2001, 68 (3) : 577-589.
  • 5Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease[J]. J Med Genet, 2002, 39(2): 91-97.
  • 6Balemans W, Van Hul W. Human genetics of SOST[J]. J Musculoskelet Neuronal Interact, 2006, 6 (4) : 355-356.
  • 7Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the Sclerostin gene in mice results in increased bone formation and bone strength[J]. J Bone Miner Res, 2008, 23 (6) : 860-869.
  • 8Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via Sclerostin, a novel BMP antagonist[J]. EMBO J, 2003, 22 (23): 6267-6276.
  • 9Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoclast -derived bone morphogenetic protein antagonist with unique ligand specificity[J]. J BioI Chem, 2003, 278(26):24113-24117.
  • 10Nemoto E, Koshikawa Y, Kanaya S, et al. Wnt signaling inhibits cementoblast differentiation and promotes proliferation[J]. Bone, 2009, 44(5): 805-812.

同被引文献17

  • 1Tian Y, Huang L, Guo YW, et al. Expression of alkaline phosphatase in immortalized murine cementoblasts in res- ponse to compression-force[J]. Saudi Med J, 2011, 32(12): 1235-1240.
  • 2Zhao M, Berry JE, Somerman MJ. Bone morphogenetic protein-2 inhibits differentiation and mineralization of ce- mentoblasts in vitro[J]. J Dent Res, 2003, 82(1):23-27.
  • 3Bao X, Liu Y, Han G, etal. The effect on proliferation and differentiation of cementoblast by using sclerostin as inhi- bitor[J]. Int J Mol Sei, 2013, 14(10):21140-21152.
  • 4Kamiya N, Kobayashi T, Mochida Y, et al. Wnt inhibitors Dkkl and Sost are downstream targets of BMP signaling through the type I A receptor (BMPRIA) in osteoblasts[J]. J Bone Miner Res, 2010, 25(2):200-210.
  • 5Devarajan-Ketha H, Craig TA, Madden B J, et al. The scle- rostin-bone protein interactome[J]. Biochem Biophys Res Commun, 2012, 417(2):830-835.
  • 6Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKKI[J]. Curt Mol Pharmacol, 2012, 5(2):153-163.
  • 7Dudley DT, Pang L, Decker S J, et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade[J]. Proc Natl Acad Sci USA, 1995, 92(17):7686-7689.
  • 8Kim HK, Oxendine I, Kamiya N. High-concentration of BMP2 reduces cell proliferation and increases apoptosis via DKK1 and SOST in human primary periosteal cells[J]. Bone, 2013, 54(1):141-150.
  • 9Delgado-Calle J, Arozamena J, P&ez-L6pez J, et al. Role of BMPs in the regulation of sclerostin as revealed by an epigenetie modifier of human bone cells[J]. Mol Cell En- docrinol, 2013, 369(1/2):27-34.
  • 10Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism[J]. Nat Chem Biol, 2008, 4(1):33-41.

引证文献3

二级引证文献11

国际口腔医学杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部